id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-E-3341-0014,FDA,FDA-2016-E-3341,Interim Extension Letter from U.S. Patent and Trademark Office to Wenderoth Lind & Ponack LLP,Other,Letter(s),2024-03-24T04:00:00Z,2024,3,2024-03-24T04:00:00Z,,2024-03-24T06:25:32Z,,0,0,090000648643a9c8
FDA-2016-E-3341-0013,FDA,FDA-2016-E-3341,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2022-05-31T04:00:00Z,2022,5,2022-05-31T04:00:00Z,,2022-05-31T14:53:02Z,,0,0,0900006483cc293f
FDA-2016-E-3341-0012,FDA,FDA-2016-E-3341,"CERTIFICATE EXTENDING PATENT TERM to Wenderoth, Lind & Ponack LLP",Other,Certificate Extending Patent Term,2020-08-20T04:00:00Z,2020,8,2020-08-20T04:00:00Z,,2020-08-20T19:12:42Z,,0,0,09000064848157a6
FDA-2016-E-3341-0011,FDA,FDA-2016-E-3341,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2020-08-20T04:00:00Z,2020,8,2020-08-20T04:00:00Z,,2020-08-20T18:27:45Z,,0,0,09000064848154f8
FDA-2016-E-3341-0010,FDA,FDA-2016-E-3341,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2019-08-05T04:00:00Z,2019,8,2019-08-05T04:00:00Z,,2019-08-05T11:52:20Z,,0,0,0900006483df159d
FDA-2016-E-3341-0009,FDA,FDA-2016-E-3341,"Letter from Wenderoth, Lind & Ponack, LLP",Other,Letter(s),2018-12-21T05:00:00Z,2018,12,2018-12-21T05:00:00Z,,2018-12-21T17:06:45Z,,0,0,09000064839c0233
FDA-2016-E-3341-0008,FDA,FDA-2016-E-3341,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2018-09-19T04:00:00Z,2018,9,2018-09-19T04:00:00Z,,2018-09-19T19:30:47Z,,0,0,0900006483727bda
FDA-2016-E-3341-0007,FDA,FDA-2016-E-3341,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2018-09-11T04:00:00Z,2018,9,2018-09-11T04:00:00Z,,2018-09-11T20:31:52Z,,0,0,09000064836dcd43
FDA-2016-E-3341-0006,FDA,FDA-2016-E-3341,Letter from RaQualia Pharma Inc.,Other,Letter(s),2018-03-19T04:00:00Z,2018,3,2018-03-19T04:00:00Z,,2018-03-19T15:28:01Z,,0,0,09000064830002d1
FDA-2016-E-3341-0005,FDA,FDA-2016-E-3341,"Determination of Regulatory Review Period for Purposes of Patent
Extension; ENTYCE",Notice,Determinations,2018-01-11T05:00:00Z,2018,1,2018-01-11T05:00:00Z,2018-03-13T03:59:59Z,2024-02-29T05:19:23Z,2018-00358,0,0,0900006482ddaca6
FDA-2016-E-3341-0004,FDA,FDA-2016-E-3341,FDA/CDER to U.S. Patent and Trademark Office,Other,Letter(s),2017-11-22T05:00:00Z,2017,11,2017-11-22T05:00:00Z,,2017-11-22T16:51:42Z,,0,0,0900006482c9f491
FDA-2016-E-3341-0003,FDA,FDA-2016-E-3341,Letter to U.S. Patent and Trademark Office,Other,Letter(s),2016-12-06T05:00:00Z,2016,12,2016-12-06T05:00:00Z,,2016-12-06T20:23:03Z,,0,0,09000064823e5906
FDA-2016-E-3341-0001,FDA,FDA-2016-E-3341,Patent Extension Application from Wenderoth Lind & Ponack LLP  ( on behalf of RaQualia Pharma Inc),Other,Application,2016-10-17T04:00:00Z,2016,10,2016-10-17T04:00:00Z,,2016-10-17T17:26:01Z,,0,0,09000064822f525e
FDA-2016-E-3341-0002,FDA,FDA-2016-E-3341,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2016-10-17T04:00:00Z,2016,10,2016-10-17T04:00:00Z,,2016-10-17T17:29:10Z,,0,0,09000064822f5260